PBAC's latest decision on Sevelamer hydrochloride: Recommended with restriction (2007). Considered for treatment of hyperphosphataemia in adults with chronic kidney disease on dialysis, whose serum phosphate is not controlled on other products and where: (a) serum phosphate is greater than 1.6 mmol per L, or (b) the serum calcium times phosphate product is greater than 4.0.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
$45k/QALY
$15k/QALY–$45k/QALY · across 3 submissions
Submissions
3
first 2006
Submissions
3
2006 → 2007
Eligible population
adults with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where: (a) serum phosphate is greater than 1.6 mmol per L, or (b) the serum calcium times phosphate product is greater than 4.0
Therapy area
Renal
Evidence base
RCT
Key trials
RIND, DCOR
Comparator
calcium carbonate
Economic model
CUA
ICER basis
Range aggregates 3 submissions (2006–2007) — not a single base case.
Submission history
Mar 2006: Not recommended · Authority Required — ICER $105k/QALY
Nov 2006: Not recommended · Authority Required — ICER $75k/QALY